4mg/ml Liquidex

[Ozzy]

Is there anyway of getting it anymore ? I don't like the **** made in alcohol these days either.

[ironfist]

That stuff hasn't been made in a long time...Good luck finding any

[Ozzy]

What is the stuff at anabolic research make there l-dex in ? Alcohol or an oil base and does ir taste like the good ole stuff ?

[956Vette]

What is the stuff at anabolic research make there l-dex in ? Alcohol or an oil base and does ir taste like the good ole stuff ?

they may have future plans to make ldex, but for now the popular AI they carry is letrozol-and it tastes great btw

[Ozzy]

they may have future plans to make ldex, but for now the popular AI they carry is letrozol-and it tastes great btw

And would you choose Letrozole over L-dex........and why ?

[956Vette]

From FContact:
"Letrozole is the superior aromatase inhibitor of the two and it increase igf-1 levels more than anastrozole, however anastrozole has shown to increase testosterone levels ."

Here is a study on anastrozole increasing T levels

posted by df2003 on musclesci


Study Shows That Arimidex Boosts Testosterone

Estrogen suppression in males: metabolic effects.
J Clin Endocrinol Metab 2000 Jul;85(7):2370-7 (ISSN: 0021-972X)
Mauras N; O'Brien KO; Klein KO; Hayes V [email protected].

We have shown that testosterone (T) deficiency per se is associated with marked catabolic effects on protein, calcium metabolism, and body composition in men independent of changes in GH or insulin -like growth factor I production. It is not clear,,however, whether estrogens have a major role in whole body anabolism in males. We investigated the metabolic effects of selective estrogen suppression in the male using a potent aromatase inhibitor, Arimidex (Anastrozole). First, a dose-response study of 12 males (mean age, 16.1 +/- 0.3 yr) was conducted, and blood withdrawn at baseline and after 10 days of oral Arimidex given as two different doses (either 0.5 or 1 mg) in random order with a 14-day washout in between. A sensitive estradiol (E2) assay showed an approximately 50% decrease in E2
concentrations with either of the two doses; hence, a 1-mg dose was selected for other studies. Subsequently, eight males (aged 15-22 yr; four adults and four late pubertal) had isotopic infusions of [(13)C]leucine and (42)Ca/(44)Ca, indirect calorimetry, dual energy x-ray absorptiometry, isokinetic dynamometry, and growth factors measurements performed before and after 10 weeks of daily doses of Arimidex. Contrary to the effects of T withdrawal, there were no significant changes in body composition (body mass index, fat mass, and fat-free mass) after estrogen suppression or in rates of protein synthesis or degradation; carbohydrate, lipid, or protein oxidation; muscle strength; calcium kinetics; or bone growth factors concentrations. However, E2 concentrations decreased 48% (P = 0.006), with
no significant change in mean and peak GH concentrations, but with an 18% decrease in plasma insulin-like growth factor I concentrations. There was a 58% increase in serum T (P = 0.0001), sex hormone-binding globulin did not change, whereas LH and FSH concentrations increased (P < 0.02, both). Serum bone markers, osteocalcin and bone alkaline phosphatase concentrations, and
rates of bone calcium deposition and resorption did not change. In conclusion, these data suggest that in the male 1) estrogens do not contribute significantly to the changes in body composition and protein
synthesis observed with changing androgen levels; 2) estrogen is a main regulator of the gonadal-pituitary feedback for the gonadotropin axis; and 3) this level of aromatase inhibition does not negatively impact either kinetically measured rates of bone calcium turnover or indirect markers of bone calcium turnover, at least in the short term. Further studies will provide valuable information on whether timed aromatase inhibition can be useful in increasing the height potential of pubertal boys with profound
growth retardation without the confounding negative effects of gonadal androgen suppression.

Again from FContact:
Here are studis on anastrozole and letrozole,

An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole.

Rose C, Vtoraya O, Pluzanska A, Davidson N, Gershanovich M, Thomas R, Johnson S, Caicedo JJ, Gervasio H, Manikhas G, Ben Ayed F, Burdette-Radoux S, Chaudri-Ross HA, Lang R.

Department of Oncology, Lund University Hospital, 221 85, Lund, Sweden. [email protected]

It was previously shown that letrozole (Femara) was significantly more potent than anastrozole (Arimidex) in inhibiting aromatase activity in vitro and in inhibiting total body aromatisation in patients with breast cancer. The objective of this study was to compare letrozole (2.5 mg per day) and anastrozole (1 mg per day) as endocrine therapy in postmenopausal women with advanced breast cancer previously treated with an anti-oestrogen. This randomised, multicentre and multinational open-label phase IIIb/IV study enrolled 713 patients. Treatment was for advanced breast cancer that had progressed either during anti-oestrogen therapy or within 12 months of completing that therapy. Patients had tumours that were either positive for oestrogen and/or progesterone receptors (48%) or of unknown receptor status (52%). The primary efficacy endpoint was time to progression (TTP). Secondary endpoints included objective response, duration of response, rate and duration of overall clinical benefit (responses and long-term stable disease), time to treatment failure, and overall survival, as well as general safety. There was no difference between the treatment arms in TTP; median times were the same for both treatments. Letrozole was significantly superior to anastrozole in the overall response rate (ORR) (19.1% versus 12.3%, P=0.013), including in predefined subgroups (receptor status-unknown, and soft-tissue- and viscera-dominant site of disease). There were no significant differences between the treatment arms in the rate of clinical benefit, median duration of response, duration of clinical benefit, time to treatment failure or overall survival. Both agents were well tolerated and there were no significant differences in safety. These results support previous data documenting the greater aromatase-inhibiting activity of letrozole and indicate that advanced breast cancer is more responsive to letrozole than to anastrozole as second-line endocrine therapy.
------------------------------------------------------------------------------
Here is a study on how letro increases IGF-1 levels

The aromatase inhibitor letrozole in advanced breast cancer: effects on serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels.

Bajetta E, Ferrari L, Celio L, Mariani L, Miceli R, Di Leo A, Zilembo N, Buzzoni R, Spagnoli I, Martinetti A, Bichisao E, Seregni E.

Medical Oncology B Division, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy.

Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels were measured in two groups of postmenopausal women with advanced breast cancer, who received the aromatase inhibitor letrozole 0.5 or 2.5 mg p.o. once daily. Blood samples were obtained from 15 patients in each dose group at baseline, and one and three months after starting therapy. Circulating IGF-I and IGFBP-3 concentrations were determined by means of radioimmunoassay. In both dosage groups a statistically significant increase in the IGF-I levels was observed during three months of letrozole treatment (P=0.003). In addition, the multiple testing procedure yielded in the whole patient population a significant result in the comparison between mean IGF-I values after three months of therapy and those observed at baseline (P=0.004), the estimated average increase being of 24%. No significant result was obtained in the analysis for the dose effect (P=0.077) and for the time x dose interaction (P=0.208). Circulating IGFBP-3 levels did not appear to be affected by letrozole treatment in either of the dose groups. This is the first report concerning the short-term effects of letrozole on components of the IGF system in breast cancer patients; further investigations are warranted in order to confirm these preliminary data.
-----------------------------------------------------------------------------
Here is another study done on letro vs nolva I posted a while back on another board.

Femara (Letrozole) More Effective Than Tamoxifen As First-Line Treatment For Advanced Breast Cancer
NEW YORK, NY -- November 9, 2000 -- New clinical findings from two studies presented for the first time in the US show Femara® (letrozole tablets) to be significantly more effective than tamoxifen (the current gold standard) in treating postmenopausal women with advanced breast cancer in both the first-line and pre-operative settings.

The trial results were presented at the Chemotherapy Foundation Symposium in New York.

In the largest study ever evaluating hormone therapy in advanced breast cancer, the number of women in whom the breast cancer had not progressed after a year of treatment was nearly 50 percent greater in patients taking Femara than in those taking tamoxifen. Femara, an aromatase inhibitor, is a once-a-day oral treatment currently indicated for treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. The FDA approved Femara for this indication 1997.

"Femara is the first breast cancer treatment to demonstrate consistent superiority over tamoxifen in multiple efficacy endpoints," said Matthew Ellis, MD, Ph.D., FRCP, Clinical Director, Duke Breast Cancer Program, Duke University Medical Center. "These study results will lead us to consider changing practice guidelines for advanced breast cancer and could pave the way for Femara as first-line therapy."

In this study of more than 900 women comparing the efficacy of Femara and tamoxifen as first-line treatment for advanced breast cancer, it was shown that Femara delays progression of advanced breast cancer for longer than tamoxifen (41 weeks vs. 26 weeks). Results also indicate significant differences between Femara and tamoxifen with respect to overall tumor response rates (30 percent vs. 20 percent), duration of clinical benefit (49 percent vs. 38 percent) and time to treatment failure (40 weeks vs. 25 weeks).

The women enrolled in this phase III randomized, double-blind multi-center trial were postmenopausal with either locally advanced (stage IIIB) disease, metastatic breast cancer or had recurrences not amenable to treatment with surgery or radiotherapy.

In this phase III randomized controlled trial of 324 postmenopausal women, patients with large localized or locally advanced breast cancer tumors were given Femara or tamoxifen as pre-operative treatment to reduce tumor size before surgery. Clinical responses after four months of preoperative therapy were significantly better for Femara than for tamoxifen (55 percent versus 36 percent) and, as a result, more women on Femara underwent breast-conserving surgery compared to tamoxifen (45 percent versus 35 percent). After adjustment for tumor size, nodal involvement and age, the odds of undergoing breast-conserving surgery were increased by more than 70 percent for Femara compared tamoxifen. In both studies, Femara and tamoxifen were equally well tolerated.

"Novartis Oncology is very encouraged by these data, which demonstrate that Femara can offer physicians and patients a drug that can make a significant impact," said David Parkinson, Vice President, Global Oncology Clinical Research at Novartis Oncology. "Femara could ultimately represent a major advance in the treatment paradigm for women with metastatic disease."

Femara is currently available in more than 75 countries worldwide. A supplemental new drug application (sNDA) was filed for Femara with the FDA for use in first-line therapy, which is currently under review. This filing has been designated for priority review. The FDA's Oncologic Drugs Advisory Committee (ODAC) will meet on December 13, 2000 to discuss the application for the first-line indication. Regulatory submissions for this indication have also been filed globally.

Femara is contraindicated in patients with known hypersensitivity to Femara or any of its excipients. Most commonly reported adverse effects with Femara in the second-line trials have been musculoskeletal pain (21 percent), nausea (13 percent), headache (9 percent), arthralgia or joint pain (8 percent), fatigue (8 percent), vomiting (7 percent), and dyspnea or labored breathing (7 percent).

[956Vette]

from lion:
Letro Raises IGF by 17 %

Letrozol is femera, which is an anti-estrogen.

Femara is 10-30x more effective than Arimidex in it's ability to pass thru the cell membrane of lipid (fat) cells and inhibit the activity of aromatase -- in other words, Femara is far superior in lowering estrogen levels in fat cells. This has two benefits for BBs; (1) Estrogen 'attracts' water, so less water retention (2) an average male BB is around 10%BF, that's a lot of lipid cells with aromatase inside them, so a substantial percentage of aromatase is left untouched by Arimidex due to it's poor ability to enter lipid cellsArimidex is approximately 80% effective at inhibiting aromatase, Femara is around 95-97%
notes:
1. J Clin Endocrinol Metab 2000 Jul;85(7):2370-7
2. J Steroid Biochem Mol Biol 1997 Nov-Dec;63(4-6):261-7